Joshua De Leon

Dr. Joshua De Leon

Department of Medicine, NYU Long Island School of Medicine, Mineola, New York, NY 11501, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 October 2021 in Metabolites
Verified
Journal Article
Open access
PDF file
JBJennifer Behbodikhah
Jennifer Behbodikhah
SASaba Ahmed
Saba Ahmed
AEAilin Elyasi
Ailin Elyasi
LKLora Janis Kasselman
Lora Janis Kasselman
JLJoshua De Leon
Joshua De Leon
ARAllison B Reiss
Allison B Reiss
Apolipoprotein (apo) B, the critical structural protein of the atherogenic lipoproteins, has two major isoforms: apoB48 and apoB100. ApoB48 is found in chylomicrons and chylomicron remnants with one apoB48 molecule per chylomicron particle. Similarly, a single apoB100 molecule is contained per particle of very-low-density lipoprotein (VLDL), intermediate density lipoprotein, LDL and lipoprotein(a). This unique one apoB per particle ratio makes plasma apoB concentration a direct measure of the number of circulating atherogenic lipoproteins. ApoB levels indicate the atherogenic particle concentration independent of the particle cholesterol content, which is variable. While LDL, the major cholesterol-carrying serum lipoprotein, is the primary therapeutic target for management and prevention of atherosclerotic cardiovascular disease, there is strong evidence that apoB is a more accurate indicator of cardiovascular risk than either total cholesterol or LDL cholesterol. This review examines multiple aspects of apoB structure and function, with a focus on the controversy over use of apoB as a therapeutic target in clinical practice. Ongoing coronary artery disease residual risk, despite lipid-lowering treatment, has left patients and clinicians with unsatisfactory options for monitoring cardiovascular health. At the present time, the substitution of apoB for LDL-C in cardiovascular disease prevention guidelines has been deemed unjustified, but discussions continue.

1 November 2018 in Atherosclerosis
Verified
Journal Article
Closed access
ARAllison B Reiss
Allison B Reiss
NMNobuyuki Miyawaki
Nobuyuki Miyawaki
JMJane Moon
Jane Moon
LKLora J. Kasselman
Lora J. Kasselman
IVIryna Voloshyna
Iryna Voloshyna
JLJoshua De Leon
Joshua De Leon

25 March 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
ARAllison B Reiss
Allison B Reiss
BJBerlin Jacob
Berlin Jacob
AZAarij Zubair
Aarij Zubair
ASAnkita Srivastava
Ankita Srivastava
Maryann JohnsonMaryann Johnson
Maryann Johnson
JLJoshua De Leon
Joshua De Leon
Chronic kidney disease (CKD) is a slowly progressive condition characterized by decreased kidney function, tubular injury, oxidative stress, and inflammation. CKD is a leading global health burden that is asymptomatic in early stages but can ultimately cause kidney failure. Its etiology is complex and involves dysregulated signaling pathways that lead to fibrosis. Transforming growth factor (TGF)-β is a central mediator in promoting transdifferentiation of polarized renal tubular epithelial cells into mesenchymal cells, resulting in irreversible kidney injury. While current therapies are limited, the search for more effective diagnostic and treatment modalities is intensive. Although biopsy with histology is the most accurate method of diagnosis and staging, imaging techniques such as diffusion-weighted magnetic resonance imaging and shear wave elastography ultrasound are less invasive ways to stage fibrosis. Current therapies such as renin-angiotensin blockers, mineralocorticoid receptor antagonists, and sodium/glucose cotransporter 2 inhibitors aim to delay progression. Newer antifibrotic agents that suppress the downstream inflammatory mediators involved in the fibrotic process are in clinical trials, and potential therapeutic targets that interfere with TGF-β signaling are being explored. Small interfering RNAs and stem cell-based therapeutics are also being evaluated. Further research and clinical studies are necessary in order to avoid dialysis and kidney transplantation.

1 September 2020 in Respiratory Investigation
Verified
Journal Article
Closed access
DGDaniel S. Glass
Daniel S. Glass
DGDavid Grossfeld
David Grossfeld
HRHeather A. Renna
Heather A. Renna
PAPriya Agarwala
Priya Agarwala
PSPeter Spiegler
Peter Spiegler
ARAllison B Reiss
Allison B Reiss

13 March 2025 in Biomolecules
Verified
Journal Article
Open access
PDF file
ARAllison B Reiss
Allison B Reiss
SGShelly Gulkarov
Shelly Gulkarov
RLRaymond Lau
Raymond Lau
SKStanislaw Klek
Stanislaw Klek
ASAnkita Srivastava
Ankita Srivastava
JLJoshua De Leon
Joshua De Leon
Worldwide, nearly 40% of adults are overweight and 13% are obese. Health consequences of excess weight include cardiovascular diseases, type 2 diabetes, dyslipidemia, and increased mortality. Treating obesity is challenging and calorie restriction often leads to rebound weight gain. Treatments such as bariatric surgery create hesitancy among patients due to their invasiveness. GLP-1 medications have revolutionized weight loss and can reduce body weight in obese patients by between 15% and 25% on average after about 1 year. Their mode of action is to mimic the endogenous GLP-1, an intestinal hormone that regulates glucose metabolism and satiety. However, GLP-1 drugs carry known risks and, since their use for weight loss is recent, may carry unforeseen risks as well. They carry a boxed warning for people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. Gastrointestinal adverse events (nausea, vomiting, diarrhea) are fairly common while pancreatitis and intestinal obstruction are rarer. There may be a loss of lean body mass as well as premature facial aging. A significant disadvantage of using these medications is the high rate of weight regain when they are discontinued. Achieving success with pharmacologic treatment and then weaning to avoid future negative effects would be ideal.

6 July 2023 in Neurology International
Verified
Journal Article
Open access
PDF file
ARAllison B Reiss
Allison B Reiss
CGCaitriona Greene
Caitriona Greene
CDChristopher Dayaramani
Christopher Dayaramani
SRSteven H. Rauchman
Steven H. Rauchman
MSMark Menniti Stecker
Mark Menniti Stecker
Aaron PinkhasovAaron Pinkhasov
Aaron Pinkhasov
SARS-CoV-2, a single-stranded RNA coronavirus, causes an illness known as coronavirus disease 2019 (COVID-19). Long-term complications are an increasing issue in patients who have been infected with COVID-19 and may be a result of viral-associated systemic and central nervous system inflammation or may arise from a virus-induced hypercoagulable state. COVID-19 may incite changes in brain function with a wide range of lingering symptoms. Patients often experience fatigue and may note brain fog, sensorimotor symptoms, and sleep disturbances. Prolonged neurological and neuropsychiatric symptoms are prevalent and can interfere substantially in everyday life, leading to a massive public health concern. The mechanistic pathways by which SARS-CoV-2 infection causes neurological sequelae are an important subject of ongoing research. Inflammation- induced blood-brain barrier permeability or viral neuro-invasion and direct nerve damage may be involved. Though the mechanisms are uncertain, the resulting symptoms have been documented from numerous patient reports and studies. This review examines the constellation and spectrum of nervous system symptoms seen in long COVID and incorporates information on the prevalence of these symptoms, contributing factors, and typical course. Although treatment options are generally lacking, potential therapeutic approaches for alleviating symptoms and improving quality of life are explored.